SCHEMBL6823936

SCHEMBL6823936

NP(=O)(O)CC1CCCCC1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 1/20 0.47
ALDH1A1 P00352 1/20 0.44
MMP2 P08253 4/20 0.44
MMP1 P03956 3/20 0.44
MMP8 P22894 3/20 0.44
CA12 O43570 3/20 0.44
CA1 P00915 3/20 0.44
CA2 P00918 3/20 0.44
CA9 Q16790 3/20 0.44
MMP3 P08254 2/20 0.44
MMP9 P14780 1/20 0.44
ALOX5 P09917 2/20 0.38
ANPEP P15144 2/20 0.37
ERAP2 Q6P179 2/20 0.37
FDPS P14324 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6828011 1.00 METAP1 (0.47) METAP1ALDH1A1MMP2MMP1MMP8
SCHEMBL6827751 0.93
SCHEMBL6827333 0.87
SCHEMBL2331815 0.80 METAP1 (0.50) METAP1ALDH1A1MMP2MMP1MMP8
Phosphoric Acid SCHEMBL11497465 0.78 METAP1 (0.48) METAP1ALDH1A1MMP2MMP1MMP8
SCHEMBL10941895 0.78 METAP1 (0.48) METAP1ALDH1A1MMP2MMP1MMP8
Water SCHEMBL7648271 0.78 METAP1 (0.48) METAP1ALDH1A1MMP2MMP1MMP8
SCHEMBL6827171 0.77 ANPEP (0.36) ALDH1A1ANPEP
SCHEMBL10715799 0.77 METAP1 (0.53) METAP1ALDH1A1MMP2MMP1MMP8
SCHEMBL6827160 0.77 ALDH1A1 (0.31) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6737416-B2 THROMBOLYTIC AGENT HAVING HIGHER SAFETY MEIJI SEIKA KAISHA LTD. (JP) 2004-05-18 US disclosed
US-20030119787-A1 Phosphonic acid derivative having inhibitory activity against carboxypeptidase B MEIJI SEIKA KAISHA LTD. (JP) 2003-06-26 US disclosed
US-6576627-B1 Such as 7-amino-2-((2-methyl-1-(3-phenylpropanoylamino)-propyl)hydroxyphosphinoyl) -methylheptanoic acid; thrombotic disease MEIJI SEIKA KAISHA LTD. (JP) 2003-06-10 US disclosed
EP-1152004-B1 Phosphonic acid derivatives having carboxypeptidase B inhibitory action MEIJI SEIKA KAISHA (JP) 2003-05-07 EP disclosed
EP-1174434-A1 Phosphonic acid derivative having inhibitory activity against carboxypeptidase B MEIJI SEIKA KAISHA LTD. (JP) 2002-01-23 EP disclosed
EP-1152004-A1 PHOSPHONIC ACID DERIVATIVES HAVING CARBOXYPEPTIDASE B INHIBITORY ACTIVITY MEIJI SEIKA KAISHA LTD. (JP) 2001-11-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119787-A1 Phosphonic acid derivative having inhibitory activity against carboxypeptidase B CPB1, RNPEP, CPN1 METAP1 36/4885ALDH1A1 1869/4885MMP2 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.